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Mycobacterium ulcerans infection: control, diagnosis, and 
treatment
Vinciane Sizaire, Fabienne Nackers, Eric Comte, Françoise Portaels
The skin disease Buruli ulcer, caused by Mycobacterium ulcerans, is the third most common mycobacterial disease 
after tuberculosis and leprosy and mainly aﬀ  ects remote rural African communities. Although the disease is 
known to be linked to contaminated water, the mode of transmission is not yet understood, which makes it diﬃ   cult 
to propose control interventions. The disease is usually detected in its later stages, when it has caused substantial 
damage and disability. Surgery remains the treatment of choice. Although easy and eﬀ  ective in the early stages of 
the disease, treatment requires extended excisions and long hospitalisation for the advanced forms of the disease. 
Currently, no antibiotic treatment has proven eﬀ  ective for all forms of M ulcerans infection and research into a new 
vaccine is urgently needed. While the scientiﬁ  c community works on developing non-invasive and rapid diagnostic 
tools, the governments of endemic countries should implement active case ﬁ  nding and health education strategies 
in their aﬀ  ected communities to detect the disease in its early stages. We review the diagnosis, treatment, and 
control of Buruli ulcer and list priorities for research and development. 
Introduction
Buruli ulcer is primarily an infection of the subcutaneous 
fat caused by the environmental pathogen Mycobacterium 
ulcerans. Although the disease has a low mortality rate, 
it  has  a  huge  socioeconomic  impact  on  aﬀ  ected 
populations  and  is  a  public-health  issue  in  terms  of 
morbidity, treatment, and functional disabilities. 
The clinical lesion of Buruli ulcer usually starts as a 
painless  subcutaneous  nodule  that  secondarily 
ulcerates, presenting characteristic undermined edges 
(ﬁ  gure  1).  Other  pre-ulcerative  forms  are  papules 
aﬀ  ecting only the skin (observed more often in Australia 
than  other  parts  of  the  world),  plaques  (large  ﬁ  rm, 
painless, and raised lesions), and oedema (severe form 
of the disease). 
M  ulcerans  produces  a  toxin,  mycolactone,  which 
induces  necrosis  and  ulceration  by  its  cytotoxic  and 
immunosuppressive properties. Some patients develop 
bone  (osteomyelitis)  and  joint  lesions  through 
contiguous  or  haematogenous  spread  of  M  ulcerans. 
Later in the natural history of the disease spontaneous 
healing  can  occur,  although  the  mechanisms  of  this 
spontaneous healing are unclear.
1 Healing takes months 
and can cause deep scarring, retractions, and deformity. 
Death is a rare complication. Various recurrence rates 
after surgical treatment have been reported, from 6·1% 
within 7 years of follow-up
2 to 16% after a follow-up 
period of 1 year.
3
Since  1980,  there  has  been  a  large  increase  in  the 
detection rate of the disease. Buruli ulcer is now the 
third most common mycobacterial infection in human 
beings after tuberculosis and leprosy, and is the most 
poorly understood of the three diseases. The disease 
often  occurs  in  localised  and  remote  areas  where 
populations have limited access to medical care. The 
median age of Buruli ulcer patients is about 15 years; 
the distribution of age-speciﬁ  c detection rates peaks at 
10–14  years  and  75–79  years.
4  Buruli  ulcer  has  been 
reported or suspected in 30 tropical countries worldwide, 
including Australia, but west Africa is the most aﬀ  ected 
region (ﬁ  gure 2).
6 Cases have also been reported in non-
tropical areas.
6 The number of cases reported in some 
countries of west Africa is substantial: 5700 between 
1989 and 2003 in Benin, with a Buruli ulcer detection 
rate  of  21·5  per  100 000  in  1999  in  the  Zou  region;
7 
17 000 between 1978 and 2003 in Côte d’Ivoire, where 
prevalence reaches 16% in some villages;
8 in Ghana, a 
national survey done in 1999 detected 5619 cases (overall 
crude national prevalence of 20·7 per 100 000 but 158·8 
per  100 000  in  the  most  aﬀ  ected  districts),  of  which 
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almost 50% were at the ulcerative stage.
9 However, most 
of these data come from passive case detection and are 
probably under-estimates of the extent of the problem 
worldwide.
10
Part of the explanation for the emerging character of 
the disease could be an increase in public and scientiﬁ  c 
awareness. Buruli ulcer has long gone largely unnoticed, 
possibly because it occurs in remote rural communities 
that are poorly covered by national health surveillance 
systems. Additionally, many of the aﬀ  ected populations 
do  not  seek  health  services  because  of  ﬁ  nancial 
constraints, beliefs that the treatment does not work, 
fear  of  surgery  and  anaesthesia,  or  superstition  and 
stigma.
11,12 However, some researchers
7,13 have concluded 
that the emergence of the disease is not only detection 
bias but also an increase in the exposure of aﬀ  ected 
populations.  Outbreaks  appear  to  be  related  to 
environmental changes (deforestation, agriculture, and 
hydraulic installations) involving surface water.
14 
Areas aﬀ  ected by Buruli ulcer disease are located near 
stagnant  or  slow-ﬂ  owing  water  areas.  Despite 
epidemiological
15  and  PCR  data
16–18  suggesting  a  link 
between  M  ulcerans  and  water,  the  transmission 
mechanism of the disease is not known. One of the 
obstacles to researching this transmission mechanism 
is the extreme diﬃ   culty in isolating M ulcerans from 
environmental  samples.  The  detection  of  the 
mycobacterium is usually done through PCR using the 
IS2404  target  but,  although  very  useful,  this  target 
might not be speciﬁ  c for M ulcerans, since it has also 
been found in other mycobacteria.
19–21 Only two pure 
cultures of M ulcerans have ever been obtained from 
environmental sources.
1 Transmission to human beings 
is probably direct, through skin trauma from the water-
soil  reservoir,  but  the  role  of  insects  is  increasingly 
suspected.
16 It has been demonstrated that the bite of 
infected  naucoridae  (aquatic  predator  insects)  can 
transmit  the  disease  to  laboratory  mice.
22  Because 
M  ulcerans  has  been  detected  by  PCR  in  diﬀ  erent 
organisms  from  the  aquatic  ecosystem,  diﬀ  erent 
experimental  models  of  transmission  with  passive 
intermediary hosts involving algae, naucoridae, aquatic 
snails,  and  ﬁ  sh  have  recently  been  suggested.
17,22,23 
M ulcerans has also been detected by PCR in mosquitoes 
in Australia, but their role in transmission has still to 
be demonstrated.
18 Migratory birds might be involved in 
the  dissemination  of  the  disease  between  wetlands, 
leading to the appearance of new foci.
17
Diﬀ  erent  factors  might  inﬂ  uence  the  clinical 
presentation of the disease—eg, the site of infection, 
the size of inoculum, the nature of the transmitting 
agent, the history of a trauma, and also the immune 
response of the host. An immune response mediated 
by Th1 lymphocytes is protective against Buruli ulcer 
disease but Th2 responses are not. It has been suggested 
that coinfection with schistosomiasis could predispose 
individuals  infected  with  M  ulcerans  to  express  the 
disease by a shift to the Th2 immune response but no 
association has been found between the two diseases.
24,25 
Strong  IgM  antibody  responses  to  M  ulcerans  seem 
more frequent in patients with active Buruli ulcer than 
in healthy members of their families.
26 HIV infection 
Figure 2: Distribution of Buruli ulcer worldwide 
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has not been reported as a risk factor for Buruli ulcer
27 
but  severe  clinical  forms  of  the  disease  have  been 
described  in  HIV-positive  patients.
28  In  three  HIV-
positive Buruli ulcer patients in Akoloninga, Cameroon, 
we observed that the healing process improved when 
the  patients  started  antiretroviral  treatment  (EC, 
unpublished data). 
Case detection and diagnosis
The burden of Buruli ulcer disease (ie, costs, extensive 
surgery,  long  hospitalisation,  and  development  of 
debilitating sequelae) is mainly due to the late detection 
of cases. Patients often seek medical treatment when 
experiencing  the  severe  and  advanced  stages  of  the 
disease. Late presentation is caused by several factors: 
(1) the disease itself—nodules can go unnoticed and 
when the ulcer appears, it progresses slowly, is painless, 
and the patient does not have systemic symptoms; (2) 
beliefs and stigma regarding the origin of the disease 
(namely  witchcraft)  making  aﬀ  ected  individuals 
reluctant  to  seek  help;  and  (3)  limited  geographic, 
ﬁ  nancial, and cultural access to medical care. 
Although the clinical diagnosis of the ulcerative form 
is straightforward, it is more diﬃ   cult for the nodule, 
plaque,  and  oedematous  forms.  The  diﬀ  erential 
diagnosis  includes  pyogenic  abscess  in  nodules, 
erysipelas in plaques, and cellulites in acute oedematous 
forms  of  the  disease.
29  In  endemic  areas,  every 
suspicious lesion should be treated as an M ulcerans 
infection until proven otherwise. 
Tests for Buruli ulcer diagnosis include the following 
methods:  (1)  direct  smear  examination  with  Ziehl-
Neelsen  staining  to  detect  the  presence  of  acid-fast 
bacilli in a smear done from a swab or a biopsy; (2) 
culture  on  Löwenstein-Jensen  medium  at  32ºC 
(however, this method is diﬃ   cult, expensive, has a low 
sensitivity,  and  results  are  available  only  after 
6–12  weeks);  (3)  histopathology;  and  (4)  PCR,  which 
allows  quick  detection,  and  is  suﬃ   ciently  speciﬁ  c in 
patient  samples  because  other  environmental 
mycobacterium will not be present in patient samples 
as they are in environmental samples, the IS2404 target 
is suﬃ   ciently speciﬁ  c.
The sensitivity of these diagnostic tests
30 is estimated 
to  be  40–80%  for  Ziehl-Neelsen  staining,  20–60%  for 
culture, over 90% for histopathology, and over 90% for 
PCR. In practice, however, the diagnosis of Buruli ulcer 
is based on clinical aspects and rarely conﬁ  rmed because 
of limited access to laboratory services. Ziehl-Neelsen 
staining  is  the  only  method  that  could  be  easily 
implemented in the ﬁ  eld. PCR is the quickest and most 
sensitive  diagnostic  tool  but,  unfortunately,  presents 
technical diﬃ   culties (eg, cold chain requirement, stable 
electric  supply  and  qualiﬁ  ed  laboratory  staﬀ  )  for  ﬁ  eld 
implementation. This technical issue could be overcome 
by the recent development of a dry reagent-based PCR.
31
According  to  WHO,  conﬁ  rmed  cases  require  two 
positive results among the diagnostic tests,
30 but WHO 
considers the possibility that one positive result might 
be suﬃ   cient in a context of a high clinical suspicion.
32
Treatment
Surgery remains the main treatment for Buruli ulcer. 
Wide excision margins, including healthy tissues, are 
recommended  to  stop  the  infection  and  prevent 
recurrence or relapse at the same site. Surgery in the 
early  stages  of  infection  is  curative  and  highly  cost-
eﬀ  ective, since it requires a simple excision followed by 
an immediate closure. However, in the disease’s later 
stages,  wide  and  traumatising  excisions  are  needed, 
followed  by  skin  grafting,  and  long  hospital  stays. 
Physiotherapy  after  surgery  might  help  to  prevent 
functional  disabilities.  To  avoid  or  limit  the  surgical 
excision,  diﬀ  erent  medical  approaches  have  been 
explored—eg,  topical  treatments,  hyperbaric  oxygen 
therapy, and antibiotic treatments (panel).
Topical treatments
Some authors have suggested that nitrogen oxides, at a 
concentration  of  6%,  could  kill  M  ulcerans  in  Buruli 
ulcer lesions quickly, as it has been shown in vitro.
33 A 
small double-blind randomised controlled trial testing 
the  daily  application  of  a  cream  releasing  nitrogen 
oxides on ulcers of less than 15 cm in diameter for at 
least 6 weeks has been done in Ghana.
34 It showed a 
signiﬁ  cant reduction of the size of the ulcer over time 
in  the  intervention  group  (p=0·03).  However,  those 
results should be interpreted with caution since the two 
groups were not comparable and only four patients had 
laboratory conﬁ  rmed disease. Further trials are needed 
to  deﬁ  ne  the  optimum  frequency  and  duration  of 
application. 
In  a  case  series
35  phenytoin  powder  appeared 
promising  in  accelerating  the  healing  process  of 
ulcerative Buruli ulcer lesions and decreasing the risk of 
hypertrophic scarring. In a small randomised controlled 
Panel: Medical treatments
(A) Topical treatments
Chemical
●  Hypochlorite
●  Chlorhexidine
●  Iodine derivated
●  Nitrites (under evaluation)
●  Phenytoin powder (under evaluation)
●  Clay (under evaluation)
Physical
●  Heat
(B) Systemic treatments (under evaluation)
●  Hyperbaric oxygen
●  Heparin
●  Antibiotics http://infection.thelancet.com   Vol 6   May 2006  291
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trial,
36 ulcer surface reduction of more than 50% was 
observed  more  frequently  in  patients  treated  with 
phenytoin powder (72%) compared with placebo (35%), 
especially in young people (<30 years) and ulcers of less 
than 30 cm in diameter. It has also been suggested that 
clay allows a quick resolution of oedema, a vigorous but 
non-aggressive  debriding  of  ulcers,  and  accelerates 
healing without surgery other than skin grafting.
37
Local  heat  at  40°C,  applied  to  eight  patients  with 
ulcers of less than 10 cm diameter in Zaire,
38 led to  
complete healing without surgery (except for the initial 
removal of necrotic tissues) and no relapse at 22 months 
of follow-up. However, the practicality of this treatment 
in remote areas (high costs, minimum infrastructure 
such as electricity, and total conﬁ  nement to bed for at 
least 2 weeks) is limited.
Systemic treatment
Although oxygen therapy seems to be ineﬀ  ective,
39 it is 
believed that antibiotic treatments, eventually combined 
with heparin, can improve the outcome of Buruli ulcer 
disease.
Reference  Treatment Objective Lesion Study design Number of 
patients
Lab 
result
Follow-up Main results Comments
Etuaful et 
al
40
Rifampicin plus 
streptomycin for 0, 
2, 4, 8, or 12 weeks
Culture 
conversion
Nodule/plaque Randomised 
controlled trial
21 Yes 12 weeks Conversion 
reached after a 
minimum of 
4 weeks
Small sample size
Kanga et 
al
41,42
Dressing plus tri-
therapy (rifampicin, 
amikacin, and 
heparin) for 
3 months vs dressing 
only
Prevent 
surgery
Ulcers Randomised 
controlled trial
50 Yes 3 months Prevents surgery 
in 80% of 
patients vs 0%
Further study needed 
to evaluate heparin 
eﬀ  ect on antibiotic 
penetration
Revill et 
al
43
Clofazimine until 
1 month after 
complete clinical 
healing 
(3–6 months)
Prevent or 
limit 
surgery
Any Randomised 
controlled trial
105 Yes Median of 
32 months 
(17–40)
No beneﬁ  t
Espey et 
al
44
Rifampicin plus 
dapsone for 
2 months
Prevent 
surgery
Ulcers 
(5–26 cm²)
Randomised 
controlled trial
30 Yes 2 months No evidence of 
beneﬁ  t
Small sample size. 
Further study needed
Fehr et al
45 Co-trimoxazole Prevent 
repetitive 
excisions
Ulcers of any 
size
Randomised 
controlled trial
12 Yes 14–77 days No evidence of 
beneﬁ  t
Small sample size. 
Further study needed
Klutse et 
al
36
Phenytoin powder 
for 8 weeks
Prevent 
surgery
Ulcers (all 
sizes)
Randomised 
controlled trial
51 No 8 weeks 40% ulcers 
healed in the 
intervention 
group compared 
with 8% in the 
placebo group
Conference abstract, 
many details missing
Phillips et 
al
34
Topical nitrogen 
oxides for 12 weeks
Avoid 
surgery
Ulcers <15 cm 
in diameter
Randomised 
controlled trial 
double blind pilot 
study
30 Yes 12 weeks Greater reduction 
of the ulcer 
surface in 
intervention 
group compared 
with the placebo 
group
Small sample size
Intervention group 
older, with ulcer of 
longer duration and 
bigger surface
Darie et 
al
46
Rifampicin, 
streptomycin, 
co-trimoxazole, 
oﬂ  oxacin, 
cephalosporin, 
penicillin A/M, 
metronidazol, or 
minocyclin for 
1 month
Decrease 
failure rate
Ulcers Observational 88 No 6 months Only 
streptomycin is 
associated with 
an acceptable 
failure rate
Meyers et 
al
38
Local heat 
(19–74 days)
Accelerate 
healing 
after 
surgery
Ulcers of 
<10 cm
Observational 8 Histo-
pathol-
ogy
22 months Healing
Brunet de 
Cours-
sou
37
Clay Avoid 
surgery
All forms Observational .. No .. Healing for small 
lesions, skin 
graft only for 
extended lesions
..=not reported.
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Many  antimicrobial  agents  have  excellent  in-vitro 
activity against M ulcerans and diﬀ  erent combinations 
inhibit growth in animals, but evidence in the treatment 
of Buruli ulcer in human beings is only anecdotal. Very 
few randomised controlled trials have been done and 
the existing ones are too small and/or not conclusive. 
The diﬃ   culty of demonstrating the beneﬁ  cial eﬀ  ects of 
antibiotics might be caused by treatment eﬀ  ects being 
undetected because of irreversible tissue damage and 
necrosis,  or  because  of  poor  irrigation  in  necrotic 
tissues hampering the penetration of the drugs into the 
tissues where M ulcerans remains. It is also possible 
that ongoing necrosis is caused by persistent toxin load 
rather  than  active  mycobacterial  infection.  Several 
antimicrobial agents have been tested in the treatment 
of Buruli ulcer as monotherapy or bitherapy (table 1).
The  use  of  monotherapies  is  generally  ineﬀ  ective. 
Clofazimine, an anti-leprosy drug evaluated in a large 
randomised  controlled  trial,
43  did  not  improve  the 
healing  process,  nor  reduce  the  number  of  surgical 
excisions,  nor  prevent  recurrences.  A  randomised 
controlled  trial  of  co-trimoxazole  (trimethoprim-
sulfamethoxazole)
45 did not show any beneﬁ  ts and was 
not conclusive because of the small sample size and 
because the treatment groups diﬀ  ered with regard to 
initial surgical treatment and duration of follow-up. In 
a  cases  series  in  Côte  d’Ivoire  in  which  diﬀ  erent 
antibiotics were used in monotherapy for 1 month, the 
lowest failure rate was associated with streptomycin.
46 
Studies in animal models showed that aminoglycosides 
(eg, streptomycin and amikacin) and rifampicin have a 
strong bactericidal activity when used alone.
47,48 However, 
M ulcerans could become resistant to rifampicin if this 
drug is used in monotherapy.
49
Based on these results and some observational studies, 
WHO recommended a combination of rifampicin and 
streptomycin for 8 weeks for the management of Buruli 
ulcer.
50 With this treatment, experts hope to reduce the 
indications  of  surgery  or,  at  least,  the  extent  of  the 
surgery and hope also to decrease the relapse rate. A 
small clinical trial showed that a minimum of 4 weeks 
of this combination inhibits the growth of M ulcerans in 
nodules and plaques, conﬁ  rmed by PCR and/or acid-
fast bacilli examination and/or culture.
40 However, the 
size of this trial is too small to conclude eﬀ  ectiveness of 
this treatment and its eﬃ   cacy in preventing relapse or 
dissemination has not yet been evaluated. 
It  has  been  suggested  that  heparin  combined  with 
rifampicin  and  aminoglycoside  treatment  could 
improve blood circulation and antibiotic penetration. A 
case  study  report  showed  excellent  results  of  this 
combination in a young girl who could not be operated 
on because of the location of the lesion on the face.
41 
This observation has been followed by a non-blinded 
randomised  controlled  trial  comparing  local  nursing 
alone with local nursing plus the tri-therapy of heparin, 
rifampicin, and amikacin.
42 In the group receiving only 
dressing  care,  100%  of  the  patients  needed  surgery, 
whereas in the group receiving the tri-therapy, only 20% 
had to go through surgery. However, the design of the 
study makes it diﬃ   cult to assess the role of heparin 
versus that of the antibiotics. 
The combination of clarithromycin and rifampicin is 
regularly used as part of standard treatment protocols 
in Australia
51 but its eﬃ   cacy has never been evaluated.
In a randomised controlled trial done in Côte d’Ivoire,
44 
the  combination  of  rifampicin  and  dapsone  showed 
ulcer size reduction in the treatment group compared 
with the placebo group but these results are inconclusive 
due to the small sample size and the imbalances of the 
ulcer size at baseline.
Some  antimicrobial  agents  have  shown  promising 
results  in  vitro  and  in  animal  models  (table  2)  but 
clinical trials are needed to assess their eﬀ  ectiveness in 
human beings. In vitro, M ulcerans is highly susceptible 
to  ﬂ  uoroquinolones
52  but  in  mice,  their  eﬀ  ect  is 
bacteriostatic.
49 Sitaﬂ  oxacin, a new ﬂ  uoroquinolone, has 
been  demonstrated  to  be  superior  to  other  ﬂ  uoro-
quinolones both in vitro and in vivo, especially when 
combined  with  rifampicin.
53,54  The  combination  of 
rifampicin, clarithromycin, and sparﬂ  oxacin has been 
tested in mice but it is not as eﬀ  ective as rifampicin 
with  an  aminoglycoside.
49,55,56  Rifalazil  (benzoxazino-
rifamycin  or  KRM-1648),  derived  from  rifampicin, 
seems to have a better inhibitory activity than rifampicin 
in  mice.
57  In-vitro  studies  showed  that  epiroprim,  a 
dihydrofolate reductase inhibitor, has a good inhibitory 
activity on the growth of M ulcerans and that there is a 
strong  synergic  activity  against  M  ulcerans
58  when 
dapsone and epiroprim are combined. At least one new 
drug  (a  diarylquinoline  known  as  R207910)  has  a 
remarkable activity in vitro against many mycobacterial 
species, including M tuberculosis and M ulcerans.
59
Overall,  no  antibiotic  combination  has  proven 
eﬀ  ective in the management of Buruli ulcer up to now. 
Despite  a  lack  of  evidence,  it  is  believed  that 
antimycobacterials  in  the  right  combination  for  the 
appropriate duration may reduce the healing time for 
ulcers and the recurrence rate, and might help avoid 
surgery or at least limit its extent. Rifampicin seems to 
Antibiotic(s) Study phase Remarks
Fluoroquinolones  In vitro/mice Bacteriostatic. Some ﬂ  uoroquinolones (eg, sparﬂ  oxacin, moxiﬂ  oxacin, 
amiﬂ  oxacin, and especially sitaﬂ  oxacin) seem to work better than others, at 
least in vitro
Rifalazil Mice  Inhibitory activity greater than rifampicin. Bactericidal towards M ulcerans
Epiroprim 
alone
58
In vitro Epiroprim > brodimoprim and K130 > trimethoprim (the last being totally 
ineﬀ  ective even at high concentration)
Epiroprim 
plus dapsone
58 
In vitro Epiroprim plus dapsone: synergic action
Brodimoprim plus dapsone: mainly additive eﬀ  ects 
Mouse results suggest that rifampicin plus epiroprim plus dapsone could be 
beneﬁ  cial in the clinical treatment of advanced ulcers
Diarylquinoline In vitro Remarkable activity
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be the key antibiotic for the treatment of Buruli ulcer 
but needs to be combined with another antibiotic to 
increase  its  eﬀ  ect  and  prevent  the  development  of 
resistance.  The  choice  between  aminoglycosides  and 
ﬂ  uoroquinolones is still debated among Buruli experts, 
even  though  WHO  issued  a  provisional  guidance  in 
2004 recommending the combination of rifampicin and 
streptomycin  for  8  weeks.
47  However,  the  long-term 
side-eﬀ  ects  of  aminoglycosides  are  quite  substantial, 
and  their  eﬀ  ectiveness  has  not  yet  been  formally 
demonstrated  by  well  conducted  clinical  trials. 
Moreover, they are contraindicated in pregnant women 
and the injectable pathway is not ideal in the context of 
the  HIV  epidemic  in  sub-Saharan  Africa. 
Fluoroquinolones  do  not  have  the  drawbacks  of  the 
aminoglycosides  and  have  good  bone  penetration. 
However,  these  drugs  are  contraindicated  in  sun 
exposure,  in  growing  children,  and  in  pregnant  and 
breast-feeding women. Another important concern is 
that  rifampicin  and  streptomycin  are  eﬀ  ective 
antituberculosis  drugs.  Their  use  in  Buruli  ulcer, 
without  excluding  concomitant  active  tuberculosis, 
might  increase  the  risk  of  developing  resistant 
tuberculosis, which could become a real threat if Buruli 
ulcer disease continues to progress as it has over the 
past 20 years. In addition, the progression of the HIV 
epidemic makes it more likely that more Buruli ulcer 
patients will be coinfected with tuberculosis. 
Control strategies
To date, public-health eﬀ  orts promoting early detection 
and rapid treatment (by active case ﬁ  nding and health 
education) have achieved the best results in terms of 
morbidity and costs of the disease.
7,60 However, unlike 
tuberculosis,  early  detection  and  treatment  will  not 
decrease  transmission,  as  human-to-human  trans-
mission is very rare. In a focus in southern Australia, 
limitation  of  irrigation  from  a  contaminated  water 
source has been associated with a dramatic reduction of 
new Buruli cases.
61 
A randomised controlled trial done in 1976 in Uganda
62 
provided evidence of a 47% short-term protective eﬀ  ect 
(6 months to 1 year) of BCG vaccination against Buruli 
ulcer. The trial did not determine whether BCG oﬀ  ered 
long-lasting protection. Two case series from Benin
63 
and Cameroon
64 suggested that BCG vaccination could 
protect  children  against  severe  forms  of  the  disease 
(osteomyelitis and multiple lesions). 
Inexpensive  prevention  strategies  such  as  wearing 
protective clothing when farming and the immediate 
cleansing  of  traumatic  skin  injuries  might  also 
help.
26,65,66
Future perspectives
The  discovery  of  the  plasmid  harbouring  the  genes 
responsible  for  mycolactone  production  and  the 
sequencing  of  the  complete  genome  of  M  ulcerans
67 
together provide a fundamental resource for researchers. 
The identiﬁ  cation of M ulcerans-speciﬁ  c antigens might 
help to develop a genetic vaccine. The knowledge of the 
genome will reveal enzymes involved in pathogenesis 
and potential virulence factors, which might promote 
the development of new drugs targeting these speciﬁ  c 
pathways.  A  better  understanding  of  the  molecular 
epidemiology might help to discover how the disease is 
transmitted.
Where do we go from here? Table 3 summarises the 
current  situation  and  future  research  needs.  More 
general data are required regarding the incidence and 
risk factors for Buruli ulcer disease.
Until the mode of transmission is fully understood, 
general environmental measures to protect communities 
cannot  be  deﬁ  ned.  If  the  role  of  aquatic  bugs  in 
transmission  or  as  intermediary  hosts  is  conﬁ  rmed, 
preventive environmental measures such as the ones 
used  for  schistosomiasis  could  be  applied—eg, 
Current situation, main problems Research and development needs
Burden of 
disease
Emerging disease due to environmental factors 
Under-reporting of the disease through passive surveillance system
Huge socioeconomic impact in the most aﬀ  ected communities mainly 
due to late diagnosis
High recurrence rate
National prevalence surveys for identifying new foci and mapping
Develop strategies for active case ﬁ  nding
Make Buruli ulcer a nationally reportable disease in aﬀ  ected areas
Improve reporting system through the existing community-based 
surveillance system 
Control of the 
disease
Mode of transmission not well understood
Eradication of the suspected water points impossible, especially in the 
most endemic countries of Africa
Identify the vectors to develop eventual vector-control strategies
Test health education and individual protective measures
Prevention of 
disease
Except BCG, which confers only a very small protection, no vaccine 
available
Development of an aﬀ  ordable and eﬀ  ective vaccine as a long-term 
objective
Diagnosis Clinical diagnosis diﬃ   cult at early stages
Invasive procedure required for sample collection at early stages 
PCR, the most sensitive tool for conﬁ  rmation, is expensive and diﬃ   cult to 
implement in the ﬁ  eld 
Produce aﬀ  ordable, rapid, and non-invasive diagnostic tests that can detect 
the early stages of the disease and are easy to implement in the ﬁ  eld
Promote outreach activities and health education strategies in endemic 
areas for early case detection
Treatment In the late stages of the disease, the treatment requires mutilating and 
expensive surgery and long hospitalisation
No antibiotic has been formally proven to be eﬀ  ective
The antibiotic treatment recommended by WHO has side-eﬀ  ects
Field-standardised measures to identify patients coinfected with 
tuberculosis
Identify new combination therapies speciﬁ  c against M ulcerans and tested 
on human patients
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improved irrigation and agriculture practices (eg, snail 
habitats could be reduced by removing vegetation, by 
draining and ﬁ  lling, or by lining canals with concrete, 
and  treating  snail-breeding  sites  with  molluscicides). 
Draining  the  water  sources  of  M  ulcerans  is  rarely 
applicable in the rural communities of Africa, unless 
access to other, safer water sources are oﬀ  ered to these 
populations. The eﬀ  ectiveness of individual protective 
measures  such  as  wearing  clothes  that  cover  the 
extremities or rubber boots when farming needs to be 
explored further.
The need for vaccination in endemic areas is clear. 
Because of the limited role of BCG, a new vaccine is 
urgently  needed  for  the  prevention  of  Buruli  ulcer. 
Among  the  prospects  for  developing  a  new  vaccine, 
non-virulent  M  ulcerans  strains  have  been  identiﬁ  ed 
and could be used for developing new vaccines.
68 Also, 
the sequencing of the M ulcerans genome could help in 
identifying  speciﬁ  c  antigens  from  which  a  plasmid 
DNA genetic vaccine could be developed.
69,70
Now  that  the  combination  of  rifampicin  and 
streptomycin  recommended  by  WHO  has  been 
implemented in several Buruli ulcer endemic countries 
(eg, Benin, Cameroon), it is diﬃ   cult to do randomised 
controlled trials to determine the eﬀ  ectiveness of this 
approach.  Therefore,  it  is  essential  to  ensure  close 
monitoring and data collection for all Buruli ulcer cases 
treated  with  the  WHO  recommended  treatment, 
describing precisely the treatment schemes in use, the 
results regarding the localisation and clinical form of 
Buruli  ulcer,  reduction  of  the  ulcer  size  or  oedema, 
speed of healing, relapse rate, side-eﬀ  ects, impact on 
the extension of the surgery, and long-term impact on 
tuberculosis (ie, the development of resistant forms). 
Additionally, feasibility and cost-eﬀ  ectiveness should be 
evaluated.  Sitaﬂ  oxacin,  rifalazil,  epiroprim,  and  the 
diaryquinolone R207910 should be tested in combination 
with other antimicrobial agents. Pharmacokinetic and/
or pharmacodynamic modelling needs to be considered 
before clinical studies are planned, so that appropriate 
human doses are used. Meanwhile, there is an urgent 
need  to  identify  cheap,  safe,  and  eﬀ  ective  oral 
combinations  of  antibiotics.  There  is  also  a  need  to 
properly  assess  the  eﬀ  ects  of  heparin  on  antibiotic 
penetration  with  studies  that  compare  groups  of 
patients on antibiotic treatment with or without heparin. 
Also,  because  the  necrotic  lesions  are  caused  by  the 
production of mycolactone, further work should look at 
the  possibility  of  developing  new  drugs  aimed  at 
inhibiting the toxin or its production. 
PCR  is  a  quick  and  sensitive  test  for  detecting 
M ulcerans, and the new dry reagent form would make 
it easier to use in practice. However, it is very expensive 
and  requires  punch  biopsies  for  the  non-ulcerative 
stage of the disease. It would be desirable to have rapid 
and non-invasive diagnostic tests that can be carried 
out  in  the  ﬁ  eld.  There  are  hopes  for  serodiagnostic 
assays for early detection based on M ulcerans-speciﬁ  c 
antigens.
1 However, it is uncertain how speciﬁ  c these 
tests will be in areas where all the members of aﬀ  ected 
communities  are  exposed  to  this  environmental 
pathogen. Also, operational research is required to test 
the eﬀ  ectiveness and applicability of these new tests in 
remote  villages  with  little  infrastructure.  Detection 
strategies  will  need  to  deﬁ  ne  the  target  groups,  the 
optimal  screening  frequency,  and  how  to  access  the 
most  aﬀ  ected  populations.  The  added  value  of  these 
tests compared with clinical examination in endemic 
areas  might  be  questionable  when  the  easiest  and 
quickest treatment of most of the nodules is excision.
Buruli  ulcer  was  declared  an  emerging  disease  in 
1998. The WHO Department of Control of Neglected 
Tropical  Diseases  has  recently  created  a  Technical 
Advisory  Group  on  Buruli  ulcer,  which  will  provide 
advice to WHO and its partners on all aspects of Buruli 
ulcer control and research. Buruli experts have invested 
much eﬀ  ort in research. The recent sequencing of the 
M ulcerans genome opens new prospects and hope for 
the future of Buruli ulcer management. However, these 
prospects  are  still  far  in  the  future,  and  such  hopes 
should not obscure the fact that when the disease is 
tackled  in  the  early  stages,  treatment  is  extremely 
simple  and  cost-eﬀ  ective.  Eﬀ  orts  should  be  directed 
towards developing strategies for early diagnosis and 
treatment of the disease, including health education for 
the  most  aﬀ  ected  populations  to  increase  awareness 
and  change  misguided  beliefs  about  the  disease, 
training of health-care workers on early detection and 
minor  surgery,  and  the  implementation  of  outreach 
activities (eg, active case ﬁ  nding, health education) in 
the most aﬀ  ected areas. 
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